World Alzheimer’s Day 2022

An estimated 50 million people around the world currently live with Alzheimer's disease or other dementias, dementia being a collective term for progressive syndromes that affect various expressions of cognitive function, such as memory and emotional expression. Alzheimer’s disease accounts for the majority of cases (50 to 70%, varying by country, based on Alzheimer’s Disease International and World Health Organization figures). For those directly affected and their loved ones, dementia can be a frightening experience, particularly as it is so poorly understood. However there remains little or no understanding of dementia in many, and the stigmatization and misinformation that surrounds dementia remains a global issue.

For 2022 World Alzheimer’s Day the theme Know Dementia, Know Alzheimer’s, organized annually by Alzheimer’s Disease International, focuses on diagnosis, the warning signs of dementia, with a special focus on post-diagnosis support. The aim of this international campaign is to highlight the importance of support for people living with dementia and families following a diagnosis.


The Lancet, Volume 396, 8 - 14 August 2020

A Commission on dementia prevention, intervention, and care, in the context of SDG 3, focusing specifically on individual-level and policy-level interventions for modifying risk factors to prevent or delay onset, tackling inequalities, providing holistic post-diagnostic care, managing neuropsychiatric symptoms, and caring for family carers.

Redox Biology, Volume 34, July 2020

Neurodegenerative diseases (NDD) such as Alzheimer's (AD) and Parkinson's disease (PD) are distinct clinical entities; however, the aggregation of key neuronal proteins, presumably leading to neuronal demise appears to represent a common mechanism. It has become evident that advanced glycation end products (AGEs) trigger the accumulation of such modified proteins, which eventually contributes to the pathological aspect of NDDs. Increased levels of AGEs are found in amyloid plaques in AD brains and in both advanced and early PD (incidental Lewy body disease). The molecular mechanisms by which AGE dependent modifications may modulate the susceptibility towards NDDs, however, remain enigmatic and it is unclear whether AGEs may serve as biomarker of NDD. This study detected differential associations between NDD, sex and oxidative stress markers.
 Imaging signature of Alzheimer's disease in adults with Down syndrome for brain structure, glucose metabolism, and amyloid β deposition.

The Lancet, Volume 395, 27 June - 3 July 2020

An article on the natural history of Alzheimer's disease in adults with Down syndrome, in the context of SDGs 3 and 10, focusing specifically on the order and timing of biomarker changes in this population.
Discrimination accuracy of models by study site.

The Lancet Global Health, Volume 8, April 2020

An article in support of SDG 3, assessing whether and to what extent existing dementia prevention models developed in high-income countries can be extrapolated to low-income and middle-income countries, where dementia risk prediction research is almost non-existent.

American Journal of Medicine, Volume 134, August 2021

Clinicians increasingly face the challenge of caring for patients who say that they would prefer death to life with advanced dementia.
The research and co-design phases of the MinD project.

Journal of Aging Studies, Volume 60, March 2022

An investigation demonstrating a way to support the well-being of people with dementia.

Experimental Eye Research, Volume 221, August 2022

This research provides the first evidence of AD-related Aβ pathology outside the brain. Lens Aβ can be noninvasively measured in vivo for early AD detection and monitoring.

The Lancet Healthy Longevity, Volume 3, June 2022

An Article on dementia risk factors, in the context of SDG 3, focusing specifically on whether cardiac multimorbidity increases dementia risk.
Graphical abstract

Free Radical Biology and Medicine, Volume 162, January 2021

Proteasome function is impaired in Alzheimer's disease (AD). Proteasome activation is followed by a decrease in amyloid-beta (Aβ) load. A reduced amount of Aβ correlates with significantly improved behavior and frailty level. Proteasome activation represents a promising intervention for alleviating AD pathology.
Alzheimer’s Disease, the dark side of the mitochondria.

Mitochondrion, Volume 64, May 2022

Alzheimer's disease (AD) is a leading neurodegenerative pathology associated with aging worldwide. It is estimated that AD prevalence will increase from 5.8 million people today to 13.8 million by 2050 in the United States alone. AD effects in the brain are well known; however, there is still a lack of knowledge about the cellular mechanisms behind the origin of AD. It is known that AD induces cellular stress affecting the energy metabolism in brain cells.